Unraveling Prurigo Nodularis - Pathogenesis, Evaluation, and Impact on Quality of Life
DermatologyManaging Prurigo Nodularis - Latest Advances and Strategies
0.25 AMA PRA Category 1 Credit(s) ™
December 22, 2023
December 22, 2024
Primary Audience:
Dermatology physicians, nurse practitioners, and physician assistants involved in the management of patients with PN.
Relevant Terms:
Pruritis nodularis, Nodular prurigo, Chronic prurigo, Lichen simplex chronicus, Itching nodules, Itchy skin nodules, Skin itching bumps
Gil Yosipovitch, MD
Miami Itch Center, Phillip Frost Department of Dermatology and Cutaneous Surgery
Miller School of Medicine
University of Miami
Miami, Florida
Gil Yosipovitch, MD is a tenured Professor and Stiefel endowed Chair of Medical Dermatology at the Dr Phillip Frost Department of Dermatology at the Miller School of Medicine at University of Miami. He is the Director of the Miami Itch Center, which focuses on chronic itch as a disease state. Prior to joining the faculty of University of Miami, Dr. Yosipovitch was Founding Chair the Department of Dermatology at Temple University and directed the first translational, clinical and research center dedicated to the study of chronic itch in the US. He has published more than 650 articles in books and peer reviewed journals and has edited 6 books with total citations in google scholar of 26500 and H index of 85. He is the founder and past President of the International Forum for the Study of Itch and member of its board. He served as Chairman of the Scientific Board of the National Eczema Association and member of the Scientific Board of The National Psoriasis Foundation and IEC and Chair of SIG of Itch in IASP. He serves on the editorial boards of 9 key specialty journals. In addition, he received one of the highest awards in dermatology, the Marion B. Sulzberger lectureship award, at the 2016 AAD meeting for his work on itch. Dr. Yosipovitch has given more than 500 invited lectures to dermatology groups and organizations around the world and has mentored more than 40 fellows, PhD students and post-Doc fellows.Timothy Berger, MD
Professor, Dermatology
University of California San Francisco
San Francisco, CA
Timothy Berger, MD earned his MD from UT Southwestern Medical School, Dallas, TX in 1975. He completed his dermatology residency at Letterman Army Medical Center in San Francisco in 1980 and then completed a dermatopathology fellowship at the Armed Forces Institute of Pathology in Washington, DC. Dr. Berger served in the Army until 1995 and obtained his first appointment to the Department of Dermatology at the University of California, San Francisco (UCSF) in 1984.Dr. Berger is currently Professor Emeritus of Clinical Dermatology. He is the former interim Department Chair (2022), Endowed Chair in Dermatology Medical Student Education, former Residency Program Director (1995-2007) and former Associate Residency Program Director (2007-2011).
In both 1991 and 2001 he was awarded Teacher of the Year by the UCSF Dermatology Residents, in 1989 he was honored with the Henry J. Kaiser Award for Excellence in Teaching and was the recipient of the 2011 UCSF Academic Senate Distinction in Teaching Award. He received the 2020 Lifetime Achievement Award from the Medical Dermatology Society, the 2021 American Academy of Dermatology Master Dermatologist Award and the 2023 Dermatology Foundation Lifetime Career Educator Awardee.
Dr. Berger has published more than 200 scientific articles, 30 book chapters and 3 books.
Dr. Berger’s has also served as the vice-president of the American Academy of Dermatology and is a past member of the Academy’s board of directors.
| 1. | Describe the pathogenesis of prurigo nodularis (PN). | 2. | Implement strategies to appropriately evaluate and timely diagnose patients with PN. |
| 3. | Summarize the impact of PN on patients' quality-of-life. |
| 1. | Describe the pathogenesis of prurigo nodularis (PN). |
| 2. | Implement strategies to appropriately evaluate and timely diagnose patients with PN. |
| 3. | Summarize the impact of PN on patients' quality-of-life. |
COURSE INFORMATION
LAUNCH DATE/EXPIRATION DATE
This activity was launched on [DATE] and will expire on [DATE].
TARGET AUDIENCE
This educational initiative has been designed for dermatology physicians, nurse practitioners, and physician assistants involved in the management of patients with PN.
ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the providership of Horizon CME. Horizon CME is accredited by the ACCME to provide continuing medical education for physicians.
CREDIT DESIGNATION
Horizon CME designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
HOW TO CLAIM CREDIT
- Read the learning objectives and faculty disclosures.
- Participate in the activity.
- Complete the post-test and activity evaluation.
- Physicians who successfully complete the post-test and evaluation will receive CME credit.
- All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.
LEARNER ASSURANCE STATEMENT
Horizon CME requires instructors, planners, managers and other individuals who are in a position to influence the content of this activity to disclose any real or apparent conflict of interest (COI) which may arise as a result of prospective faculty members' relevant relationships with drug or device manufacturer(s). Horizon CME is committed to resolving all conflicts of interest and retaining only those speakers with financial interest conflicts that can be reconciled with the goals and educational integrity of the CME activity.
COURSE FACULTY
Gil Yosipovitch, MD
Miami Itch Center, Phillip Frost Department of Dermatology and Cutaneous Surgery
Miller School of Medicine
University of Miami
Miami, Florida
Dr. Yosipovitch discloses that he is on an advisory board for AbbVie, Arcutis, CARA, Galderma, Incyte and Sanofi Regeneron and Vifor as well as a consultant for AbbVie, CARA, Escient, Galderma, Pfizer, Sanofi Regeneron and Vifor. He also is an investigator and/or receives grant support from AbbVie, Arcutis, CARA, Escient, Galderma, Incyte, Pfizer, Sanofi Regeneron and Vifor. Dr. Yosipovitch is on a committee for Pfizer, during the past 24 months.
Timothy Berger, MD
Professor Emeritus of Clinical Dermatology
University of California San Francisco
San Francisco, CA
Dr. Berger discloses he is on a speaker’s bureau for Sanofi-Regeneron, during the past 24 months.
OTHER CONTRIBUTOR/PLANNER DISCLOSURES
Those others involved in the planning of this activity disclosed no relevant financial relationships with any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients.
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
SUPPORTER ACKNOWLEDGMENT
This activity is supported by an independent educational grant from Sanofi and Regeneron Pharmaceuticals.
COURSE VIEWING REQUIREMENTS
| Supported Browsers: Microsoft Edge Google Chrome 60 or higher Mozilla Firefox 60 or higher Apple Safari 11.0 or higher For video, install the latest version of Quicktime. | Supported Phones & Tablets: iOS 9.3 and higher Android 7.0 (Nougat or higher) Microsoft Windows 8 Chrome OS |
| Additional Recommendations and Requirements | |
| Display Resolution & Color Depth | Resolution - 960 X 768 minimum - 1024 X 768 recommended min. Color Depth - 8 bits (256 colors) minimum - 16 bits (High colors) minimum |
| Audio | - Microphone - Speakers or headphones - Audio recording support |
| Word Processing | Software that can open, modify, and save documents in Rich Text Format (RTF). Microsoft Word and PowerPoint are recommended. |
